Eliem Therapeutics, Inc.
ELYM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $276 | $73 | $97 | $274 |
| - Cash | $87 | $93 | $44 | $47 |
| + Debt | $1 | $0 | $0 | $0 |
| Enterprise Value | $190 | -$20 | $53 | $227 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$82 | -$14 | $1 | -$36 |
| % Margin | – | – | – | – |
| Net Income | -$74 | -$35 | -$45 | -$47 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.53 | -1.3 | -1.72 | -1.81 |
| % Growth | -17.7% | 24.4% | 5% | – |
| Operating Cash Flow | -$16 | -$21 | -$37 | -$36 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$16 | -$21 | -$37 | -$36 |